Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661420 · ClinicalTrials.gov registry record · Phase 1
211At-MABG in Adults With Advanced Neuroendocrine Cancers
A Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07661420: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT07661420 is a Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07661420, a Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Primary Outcome
Proportion of intended 211At-MABG fractionated doses that are successfully administered within the protocol-defined window (at the overall study level).
Interventions
- DRUG 1 MBq/k of 211At-MABG Fractionated
- DRUG 2 MBq/k1 of 211At-MABG Fractionated
- DRUG 4 MBq/k of 211At-MABG Fractionated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2032-08-01 |
| Phase | Phase 1 |
What is known before NCT07661420 opens enrollment
NCT07661420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which 1 MBq/k of 211At-MABG Fractionated is the first listed.
NCT07661420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07661420 about?
NCT07661420 is a clinical study titled "211At-MABG in Adults With Advanced Neuroendocrine Cancers". Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standar...
What is the current status of trial NCT07661420?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-08-01. Estimated completion is 2032-08-01.
What interventions are being tested in trial NCT07661420?
The interventions under investigation include: 1 MBq/k of 211At-MABG Fractionated (DRUG), 2 MBq/k1 of 211At-MABG Fractionated (DRUG), 4 MBq/k of 211At-MABG Fractionated (DRUG).
Who is sponsoring clinical trial NCT07661420?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07661420's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI